Interactions of organophosphate flame retardants with human drug transporters.


Journal

Ecotoxicology and environmental safety
ISSN: 1090-2414
Titre abrégé: Ecotoxicol Environ Saf
Pays: Netherlands
ID NLM: 7805381

Informations de publication

Date de publication:
15 Sep 2023
Historique:
received: 10 06 2023
revised: 04 08 2023
accepted: 07 08 2023
medline: 20 9 2023
pubmed: 20 8 2023
entrez: 19 8 2023
Statut: ppublish

Résumé

Organophosphate flame retardants (OPFRs) are environmental pollutants of increasing interest, widely distributed in the environment and exerting possible deleterious effects towards the human health. The present study investigates in vitro their possible interactions with human drug transporters, which are targets for environmental chemicals and actors of their toxicokinetics. Some OPFRs, i.e., tris(2-butoxyethyl) phosphate (TBOEP), tris(1,3-dichloroisopropyl) phosphate (TDCPP), tri-o-cresyl phosphate (TOCP) and triphenyl phosphate (TPHP), were found to inhibit activities of some transporters, such as organic anion transporter 3 (OAT3), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter 2 (OCT2) or breast cancer resistance protein (BCRP). These effects were concentration-dependent, with IC

Identifiants

pubmed: 37597291
pii: S0147-6513(23)00852-7
doi: 10.1016/j.ecoenv.2023.115348
pii:
doi:

Substances chimiques

tri-o-cresyl phosphate X8II18JD0A
ATP Binding Cassette Transporter, Subfamily G, Member 2 0
Flame Retardants 0
Neoplasm Proteins 0
triphenyl phosphate YZE19Z66EA
Tritolyl Phosphates 0
Membrane Transport Proteins 0
Environmental Pollutants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115348

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Valentin Tastet (V)

Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

Marc Le Vée (M)

Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

Marie Kerhoas (M)

Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

Anna Zerdoug (A)

Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

Elodie Jouan (E)

Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

Arnaud Bruyère (A)

Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

Olivier Fardel (O)

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé), France. Electronic address: olivier.fardel@univ-rennes1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH